| 0.42 Data as of May 24 |  -0.005 / -1.18%Today’s Change | 0.28 Today|||52-Week Range 0.89 | -22.94% Year-to-Date |
| SECTOR Process Industries | INDUSTRY Industrial Specialties | MARKET CAP $129.9M |
Company Description
A.P. Pharma, Inc. is a pharmaceutical company. It designs and commercializes of polymer technologies for pharmaceutical and other applications. The company develops products using its proprietary Biochronomer polymer based drug delivery technology. Its primary focus is on its product, APF530, for the prevention of chemotherapy induced nausea and vomiting. The company has additional clinical and preclinical-stage programs in the area of pain management, all of which utilize its bioerodible, injectable and implantable delivery systems. Its Biochronomer technology is applicable to a range of therapeutics areas, including prevention of nausea and vomiting, pain management, control of inflammation and treatment of ophthalmic diseases. The company was founded in February 1983 and is headquartered in Redwood City, CA.
Employees
Shareholders
| Other institutional | 61.21% |
| Individual stakeholders | 23.35% |
| Mutual fund holders | 14.75% |
Top Executives
| Barry D. Quart, PharmD | Chief Executive Officer & Director |
| Robert Rosen | President & Director |
| Stephen R. Davis, CPA | Chief Operating Officer, Director & Executive VP |
| John B. Whelan, MBA | Chief Financial Officer |
| Mark S. Gelder | Chief Medical Officer & Senior Vice President |
.
